Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

Swiss pharmaceutical company Novartis announced the results of a Phase II/III study showing that the combination of the targeted therapies Tafinlar (dabrafenib) and Mekinist (trametinib) outperforms chemotherapy in pediatric low-grade glioma (pLGG) patients harboring the BRAF V600 mutation.